Prostate Cancer Study Shows Hypofractionation Comparable to Standard Radiation in Low-risk Patients
October 21st 2015Hypofractionated radiotherapy can achieve similar cure rates with similar side effects compared with conventional radiotherapy for men with low-risk, early prostate cancer, according to a recent study.
Read More
Dr. Sylvia Asa on Thyroid Cancer Genotyping
October 20th 2015Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Watch
Survey Reveals Wide Variation in the Treatment of Thyroid Nodules
October 20th 2015Dr. Nicole O. Vietor presented a report assessing practice discordances related to previously published guidelines published from the American Thyroid Association and the American Association of Clinical Endocrinologists.
Read More
Lenvatinib Extended Progression-Free Survival in Patients With Metastasis
October 20th 2015Patients in a lenvatinib treatment arm with radioiodine-refractory differentiated thyroid cancer and certain metastasis experienced a much better overall median progression-free survival compared with a placebo arm.
Read More
Everolimus Reduces Risk of Progression and Death in Lung/GI NETs
October 20th 2015Everolimus demonstrated a 52% reduction in the risk of progression or death in patients with lung/gastrointestinal neuroendocrine tumors, improving progression-free survival by 7.1 months compared with placebo.
Read More
Dr. Matthew H. Kulke Talks About Telotristat Etiprate Benefitting Carcinoid Syndrome Patients
October 20th 2015Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.
Watch
Unprecedented PFS in Midgut NETs Shown With Lu-Dotatate
October 20th 2015Results from NETTER-1 trial showed an unprecedented 79% reduction in the risk of progression or death with the radiopharmaceutical Lu-Dotatate compared with high-dose octreotide LAR (60 mg) in patients with progressive, metastatic midgut neuroendocrine tumors (NETs).
Read More
Dr. Jay Ciezki Talks About the Benefits of Stereotactic Body Radiation Therapy
October 20th 2015Jay Ciezki, MD, staff member of the Department of Radiation Oncology at Cleveland Clinic and Department of Cell Biology at Cleveland Clinic, talks about the potential advantages of utilizing Stereotactic Body Radiation Therapy in prostate cancer patients.
Read More
Coordination of Care Based on Patient-Reported Outcomes Improves End-of-Life Care and Lowers Costs
October 19th 2015Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.
Read More
Efficacy of Lanreotide for the Treatment of Neuroendocrine Tumors
October 17th 2015Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Watch
NANETS Symposium to Feature Important Late-Breaking Trials
October 13th 2015The 2015 NANETS Annual Symposium begins October 15 and the theme focuses on a team perspective. Kari Brendtro, founder of NANETS, recently spoke with Targeted Oncology about some of this year's upcoming presentations.
Read More
EGFR-Positive Squamous NSCLC Survival Improved by Cetuximab
September 15th 2015When cetuximab (Erbitux) was added to chemotherapy, the risk of death was reduced by 44% for patients with advanced squamous non-small cell lung cancer (NSCLC) whose tumors test positive for EGFR gene amplification.
Read More
High Response Rate Produced by Osimertinib in EGFR T790M-Mutant NSCLC
September 15th 2015Osimertinib (AZD9291), the third-generation TKI, demonstrated a 71% objective response rate (ORR) in those with EGFR T790M-mutant non-small cell lung cancer (NSCLC), following resistance to frontline anti-EGFR therapy.
Read More
Better Survival for Necitumumab With Chemotherapy in Metastatic Squamous NSCLC
September 11th 2015For patients who have metastatic squamous non-small cell lung cancer (NSCLC) whose tumors were positive for EGFR copy number, as determined by the FISH analysis, survival tended to be better with the addition of necitumumab to their conventional chemotherapy.
Read More